Alkem Laboratories has launched Perampil (Perampanel) tablets 2 mg/4 mg/6 mg on June 9, 2021 to make the treatment accessible to patients and healthcare providers improving their quality of life. Alkem has launched Perampil, at 2 mg Rs 49 per strip of 7 tablets, 4 mg Rs 180 per strip of 15 tablets and 6 mg – Rs 300 per strip of 15 tablets, to improve patient access.
This product reaffirms Alkem’s commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India. Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
